Tim Harkness, Unchained Labs CEO
April 26, 2021 10:59 AM EDT
Deals

The Car­lyle Group shells out $435M for con­trol­ling stake in vac­cine, gene ther­a­py ser­vices com­pa­ny

Josh Sullivan

The Car­lyle Group has put a tar­get on life sci­ences in re­cent years, look­ing for op­por­tu­ni­ties to take con­trol­ling stakes in promis­ing firms. Af­ter shelling …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times